U.S., May 13 -- ClinicalTrials.gov registry received information related to the study (NCT07580638) titled 'Chiglitazar Added to SGLT-2 Inhibitors for Type 2 Diabetes' on April 22.
Brief Summary: The goal of this observational study is to evaluate the comprehensive clinical efficacy, cardiovascular, renal, and hepatic benefits, as well as the safety of adding Chiglitazar to SGLT-2 inhibitor therapy in adult patients with Type 2 Diabetes Mellitus (T2DM) . The main questions it aims to answer are:
What is the real-world effectiveness of Chiglitazar, when added to an SGLT-2 inhibitor, on glycemic control? What are the effects of this combination therapy on cardiovascular, renal, and hepatic outcomes? What is the overall safety of this treatm...